Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
Background/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the p...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Turkish Society of Gastroenterology
2019-08-01
|
| Serie: | The Turkish Journal of Gastroenterology |
| Soggetti: | |
| Accesso online: | https://turkjgastroenterol.org/index.php/tjg/article/view/3459 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|